clinical rational for lumbar fusion surgery. Patients who underwent a ALIF, PLF or T/PLIF with Љstand-aloneЉ DDD had significantly lower total payments and significantly shorter LOS, while patients with DDD and additional back diagnoses had significantly higher total payments and longer LOS compared to patients who underwent an ALIF, PLF, or T/PLIF without a comorbid diagnosis of DDD.
OBJECTIVES: Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by benign tumor growth in multiple organs. TSC's subsequent and varied impacts on patients are typically treated by many different types of procedures. This study aimed to assess the principal clinical manifestations imposed by the disease and consequent major types of health care resource utilization experienced among TSC patients in the United States (US). METHODS: An Institutional Review Board-approved Internet-based survey of US TSC patients and caregivers solicited information on prevalence of manifestations, disease management, and impact on patients. Descriptive statistics were calculated. RESULTS: Of the 380 initial respondents, 53% were patients and 47% were caregivers. Surveys provided data on 380 patients, of whom 59% were female and the mean age was 30.4 years (SD: 17.3; median: 32.5). The majority of patients reported experiencing skin lesions (53%) while seizures, cognitive concerns, cerebral tumors, angiomyolipomas (AML), and subependymal giant cell astrocytomas (SEGA) were reported by 46%, 36%, 26%, 23%, and 21%, respectively. Ninety patients (24%) reported only one manifestation of TSC, while 18%, 14%, and 38% reported 2, 3, or 4 or more. Over half of patients (52%) had some type of TSC-related surgery including but not limited to brain surgery (33%), embolization (12%), nephrectomy (7%), kidney transplant (6%), and laser surgery (12%). Patients with SEGAs reported the highest level of brain surgery (55%). Among patients with AMLs, embolization for kidney lesions (28%), nephrectomy (12%) and kidney transplant (8%) were reported. CONCLUSIONS: In this analysis of initial respondents, TSC presents significant, and varied, epidemiological and clinical burden in the US. Patients with SEGA and AMLs seemed to experience the highest rates of invasive procedures among all patients with TSC.
PSU34 EPIDEMIOLOGICAL MODELING OF PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION IN GERMANY
Jugl S, Langsdorf V, Schüle S Novartis Pharma GmbH, Nuremberg, Bavaria, Germany OBJECTIVES: The number of performed heart transplantations per year are well published and can easily be accessed. Nevertheless, there are no exact figures on the prevalence and incidence of patient survival after heart transplantation in Germany, although these patients have high health care needs. Purpose of this study was to generate these missing figures for the past and present as well as taking an outlook into the future development until 2030. METHODS: Primarily based on statistics from the Federal Statistical Office and liver transplant quality reports of the German AQUA-Institute, relevant parameters and data were identi-fied and used to develop an epidemiological model. Key drivers of the model are yearly patient survival rates as well as growth rates of performed liver transplantations. The model starts in 1987 and is able to predict the future development of the cumulative liver transplant patient population until the year 2030. To account for uncertainty, a 1.000 replication Monte-Carlo-Simulation with random samples within published ranges of the input parameters was run. RESULTS: According to our model currently (2012) about 7.773 (95% Confidence interval: 7.701 -7.844) patients with prior liver transplantation live in Germany. Until 2030 the model estimates an increase of the population size to people. The number of performed liver transplantations is estimated at 3.068 (95% CI: 2.988 -3.148) in 2030. CONCLUSIONS: With current assumptions the liver transplant patient population size will continuously grow. The growth of this population will primarily be limited by available organs for transplantation.
PSU35 EPIDEMIOLOGICAL MODELING OF PATIENT SURVIVAL AFTER HEART TRANSPLANTATION IN GERMANY
Jugl S, Langsdorf V, Schüle S Novartis Pharma GmbH, Nuremberg, Bavaria, Germany OBJECTIVES: The number of performed heart transplantations per year are well published and can easily be accessed. Nevertheless, there are no exact figures on the prevalence and incidence of patient survival after heart transplantation in Germany, although these patients have high health care needs. Purpose of this study was to generate these missing figures for the past and present as well as taking an outlook into the future development until 2030. METHODS: Primarily based on statistics from the Federal Statistical Office and heart transplant quality reports of the German AQUA-Institute relevant parameters and data were identified and used to develop an epidemiological model. Key drivers of the model are yearly patient survival rates as well as growth rates of performed heart transplantations. The model starts in 1980 and is able to predict the future development of the cumulative heart transplant patient population until the year 2030. To account for uncertainty, a 1.000 replication Monte-Carlo-Simulation with random samples within published ranges of the input parameters was run. RESULTS: According to our model currently (2012) about 4.072 (95% Confidence interval: 4.028 -4.116) patients with prior heart transplantation live in Germany. Until 2030 the model estimates a decrease of the population to 3.028 (95% CI: 2.980 -3.077) people. Peak number of patients after heart transplantation was estimated at 2007: 4.225 (95% CI: 4.192 -4.257 ). The number of performed heart transplantations is estimated at 266 (95% CI: 261-271) in 2030. CONCLUSIONS: Even though the peak number of patients with heart transplants according to our model has occurred in the past, still a considerable heart transplant patient population is living at Germany and seeking health care services for their needs.
